A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis

Neurology

Volumn 74, Issue 23, 2010, Pages 1852-1859

  Burton, J M ^a,b   Kimball, S ^b,c   Vieth, R ^b,c   Bar Or, A ^d,e   Dosch, H M ^b,f   Cheung, R ^b,f   Gagne, D ^d,e   D'Souza, C ^b,g   Ursell, M ^h   O'Connor, P ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

^h Etobicoke General Hospital   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE BONE ISOENZYME; ASPARTATE AMINOTRANSFERASE; BIOCHEMICAL MARKER; CALCIUM; CALCIUM PHOSPHATE; COLECALCIFEROL; CREATININE; GAMMA INTERFERON; GELATINASE B; GLATIRAMER; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; METHYLPREDNISOLONE; PARATHYROID HORMONE; PREDNISONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; UREA;

ABSENCE OF SIDE EFFECTS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CALCIUM URINE LEVEL; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; DEMOGRAPHY; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; FATTY LIVER; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; OPEN STUDY; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT DURATION; UREA BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

ADOLESCENT; ADULT; AGE FACTORS; CALCIUM; CASE-CONTROL STUDIES; CELL PROLIFERATION; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VITAMIN D; VITAMINS; YOUNG ADULT;

EID: 77953328331     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181e1cec2     Document Type: Article

References (21)

1. Ulett G. Geographic distribution of multiple sclerosis. Dis Nerv Syst 1948;9:342.
2. Acheson ED, Bachrach CA, Wright FM. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation and other variables. Acta Psychi-atr Neurol Scand 1960;suppl 147:132-147.
3. van der Mei IA, Ponsonby AL, Blizzard L, et al. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuro-epidemiology 2001;20:168-174.
4. van der Mei IA, Ponsonby AL, Blizzard L, et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ 2003;327:316.
5. Islam T, Gauderman WJ, Cozen W, et al. Childhood sun exposure influences risk of multiple sclerosis in monozy-gotic twins. Neurology 2007;69:381-388.
6. Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832-2838.
7. Vieth R, Bischoff-Ferrari H, Boucher BJ, et al. The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr 2007;85:649-650.
8. Soilu-Hanninen M, Airas L, Mononen I, et al. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler 2005;11:266-271.
9. Soilu-Hannien M, Laakson M, Laitinen I, et al. A longitudinal study of serum 25-hydroxyvitamin DD and intact PTH levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008;79:152-157.
10. Embry AF, Snowdon LR, Vieth R. Vitamin D and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2000;48:271-272.
11. Cantorna MT, Humpal-Winter J, DeLuca F. Dietary calcium is a major factor in 1-25-dihydroxycholecalciferol suppression of experimental autoimmune encephalomyeli-tis in mice. J Nutr 1999;129:1966-1971.
12. Smolders J, Damoiseaux J, Menheere P, et al. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol 2008;194:7-17.
13. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999;69:842-856.
14. Kimball SM, Ursell MR, O'Connor P, et al. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr 2007;86:645-651.
15. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2003;50:121-127.
16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale. Neurology 1983;33:1444-1452.
17. Banwell B, Bar-Or A, Cheung R, et al. Abnormal T-cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes. Ann Neurol 2008;63:98-111.
18. Fordyce CB, Gagne D, Jalili F, et al. Elevated serum inflammatory markers in post-poliomyelitis syndrome. J Neurol Sci 2008;271:80-86.
19. Wingerchuk DM, Lesaux J, Rice GPA, et al. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005;76:1294-1296.
20. Goldberg P, Fleming MC, Picard EH. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypoth 1986;21:193-200.
21. Noseworthy JH, Ebers GC, Vandervoot MK, et al. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology 2001; 57(12 suppl 5):S31-35.